GlassScriptPhysician profile
Irene C Viola
NPI 1386699122
$15,044.18
in general payments reported to CMS, 2019-2025
35 companies · $1,957 in 2025
The $1,957 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,775 · 2020: $1,118 · 2021: $1,956 · 2022: $1,950 · 2023: $2,210 · 2024: $2,078 · 2025: $1,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,006 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,005.97 |
| Education | $238.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,039.01 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $3,018.37 | 2019-2025 | Enbrel, Otezla, Otezla |
| Janssen Biotech, INC. | $2,102.26 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,331.97 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $784.75 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $643.44 | 2019-2020 | |
| Pfizer INC. | $482.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $479.06 | 2021-2024 | Breztri, Saphnelo, Airsupra |
| Celgene Corporation | $346.41 | 2019 | |
| Novo Nordisk INC | $317.26 | 2019-2025 | Ozempic, Wegovy |
| Mallinckrodt Enterprises LLC | $278.40 | 2019 | |
| Genentech USA, INC. | $266.05 | 2023-2025 | Actemra |
| Glaxosmithkline, LLC. | $231.74 | 2019-2025 | Benlysta |
| Exact Sciences Corporation | $177.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Radius Health, INC. | $143.51 | 2019-2025 | Tymlos |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $122.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $119.02 | 2023 | Rexulti |
| Mallinckrodt Hospital Products INC. | $107.27 | 2020-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $104.40 | 2023-2025 | Strensiq |
| Johnson & Johnson Health Care Systems INC. | $103.57 | 2025 | Tremfya |
| Sanofi Pasteur INC. | $95.20 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $95.00 | 2020 | |
| Boston Scientific Corporation | $86.57 | 2025 | Spyglass Discover |
| Genzyme Corporation | $80.58 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $67.34 | 2023-2024 | Idacio |
| Sandoz INC. | $64.27 | 2023-2024 | Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $47.08 | 2019-2024 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.49 | 2019 | |
| Medexus Pharma, INC. | $40.74 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.95 | 2022 | |
| Pacira Therapeutics, INC. | $23.20 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.78 | 2022 | |
| Orthogenrx INC. | $15.90 | 2019 | |
| Merck Sharp & Dohme LLC | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irene Viola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.